This research develops “nanozymes,” nanoparticle-based catalysts that activate cancer drugs directly at tumor sites. Instead of carrying large amounts of chemotherapy drugs, nanozymes locally trigger inactive drugs into their active form only within cancer tissue. Early mouse studies show effective tumor destruction with significantly reduced side effects compared to conventional chemotherapy.

This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.

This research develops an inhalable treatment for lung infections using nanocrystalline silver with both antimicrobial and anti-inflammatory properties. By adapting proven skin-based technology for respiratory delivery via nebulization, it targets both pathogens and harmful inflammation, addressing a major gap in lung disease treatment affecting over a billion people worldwide.

This project develops an “Aptamer Express,” a DNA-based Trojan horse designed to bypass the brain’s protective barriers, target tumours, and deliver cancer-killing drugs directly to brain cancer cells. The approach aims to overcome treatment resistance, improve precision, and reduce side effects, offering new hope for patients and their families.

My research develops a gentle cancer treatment using ultrasound to activate specialised LDH particles inside tumour cells. These particles release ROS “micro-explosions” that kill cancer without surgery or chemotherapy. Enhanced with MRI-visible metals, the method offers a safe, targeted therapy that destroys breast cancer cells using sound instead of pain.